Current and proposed biologic markers in
โ
David G. Bostwick; Rodolfo Montironi; Raymond Nagle; Thomas Pretlow; Gary Miller
๐
Article
๐
1992
๐
John Wiley and Sons
๐
English
โ 249 KB
This approach is more practical than waiting for clinical development of cancer because a shorter time is needed to obtain results, particularly with relatively slow-growing tumors such as prostate cancer. However, the use of intermediate endpoints is limited by their predictive ability; this is a d